Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  15: Apr | Mar | Feb | Jan | 14: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/16/2015 > 153 patent applications in 89 patent subcategories.

20150104380 - Biodegredable carrier for carrying radioisotope and kit containing the same: The present invention relates to a biodegradable carrier for carrying a radioisotope, which is formed from at least one biodegradable polymer selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(ε-caprolactone) (PCL), chitosan, poly(γ-glutamic acid) (PGA), and polyethylene glycol (PE) in which its hydroxyl group is substituted... Agent:

20150104381 - Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound... Agent: Biosynthema Inc.

20150104382 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin: Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal... Agent:

20150104383 - Selenocysteine mediated hybrid antibody molecules: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as... Agent:

20150104384 - Amido-benzyl sulfone and sulfoxide derivatives: The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.... Agent:

20150104385 - Radio-pharmaceutical complexes: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has... Agent: Algeta Asa

20150104386 - Isotope preparation method: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using... Agent:

20150104387 - Psma-targeting compounds and uses thereof: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.... Agent: The Johns Hopkins University

20150104388 - Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and... Agent:

20150104389 - Radiolabelled glutaminyl cyclase (qc) inhibitors and uses of same: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.... Agent:

20150104390 - All-protein implantable, resorbable reflectors: The invention provides for compositions and process for fabricating an optical reflector constructed from biocompatible and bioresorbable silk fibroin proteins. For example, the silk retroreflectors may be built based on millimeter size microprism arrays to rotate the image plane of imaged cortical layers, thus enhancing the amount of photons that... Agent:

20150104392 - Compositions, biomarkers and their use in the treatment of cancer: The present invention relates to compositions, biomarkers, and their use in treatment of cancer. In some embodiments, the invention relates to the use of several biomarkers in methods for determining the responsiveness of a human subject to a specific compound, methods for monitoring the efficacy of the compound, or methods... Agent:

20150104391 - Method for preparing patient-specific glioblastoma animal model, and uses thereof: Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a... Agent: Samsung Life Public Welfare Foundation

20150104393 - Nutrient combinations for affecting an aging process: A composition comprising an effective amount of a combination of mitochondrial nutrients sufficient to affect mitochondrial function. A method of affecting an aging process in a subject comprising administering to a subject an effective amount of a combination of mitochondrial nutrients sufficient to affect an aging process. A method of... Agent:

20150104394 - Characterization of biological tissues at a cellular level using red and far-red fluorescent dyes: A method for observing the morphology of a biological tissue is disclosed. The method involves using a fluorescent dye on the biological tissue, where the fluorescent dye is selected from patent blue V, isosulfan blue, toluidine blue, hypericin, indocyanine green, MVAC, or doxorubicin, and using a microscopic linear or non-linear... Agent: Igr-institut Gustave Roussy

20150104396 - Method for detecting cancer using icg fluorescence method: A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence... Agent:

20150104395 - System and method for diagnosis of astrocytic brain tumor: Methods and systems for distinguishing an astrocytic human brain rumor from a non-astrocytic human brain tumor (FIG. 4). In one embodiment a method includes the steps of staining tumor tissue from a subject suspected of having a brain tumor with SR101 and visualizing the tissue stained with SR101 with a... Agent: Dignity Health

20150104397 - Aerosol device based on a calcium salt and a fixing polymer: The invention relates to an aerosol device containing a cosmetic composition comprising: (i) from 0.1% to 15% by weight relative to the total weight of the composition, of one or more water-insoluble calcium salts, (ii) one or more fixing polymers, (iii) one or more C2-4 monoalcohols, and (iv) one or... Agent:

20150104398 - Taste modulator and method of use thereof: The present invention is directed to a novel taste-masking composition comprising a taste-masking effective amount of an Angelica root extract, which shows unexpected effectiveness in reducing an undesirable taste in a food product (e.g., a beverage, broth, or whole grain food product), a dental product, an oral hygiene product or... Agent:

20150104399 - Prevention of fibroblast collapse: The present technology is directed to extracts of plants of genus Osmanthus, skin care compositions comprising extracts of plants of the genus Osmanthus; as well as to methods of formulating skin care compositions, and methods of reducing or preventing fibroblast collapse, reducing or preventing glycation, maintaining or increasing skin elasticity... Agent: Biocogent, LLC

20150104400 - Topical delivery and administration system for stabilized protection agent, compositions and methods of making same: The present invention provides a method and product for topical delivery and administration of stabilized protection agents and compositions thereof and methods for making the composition and use thereof. The method and system comprises pharmaceutical compositions for facilitating topical delivery of protection agents and skin anti-photoaging agents for inhibiting cellular... Agent:

20150104401 - Cationic polyglyceryl compositions and compounds: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently... Agent:

20150104402 - Cationic polyglyceryl compositions and compounds: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently... Agent:

20150104403 - Cationic polyglyceryl compositions and compounds: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently... Agent:

20150104404 - Polymer synergy for improved hair styling: A hair styling composition comprises: 5 wt. % to 50 wt. % of a first nonionic polymer; 2 wt. % to 20 wt. % of a second nonionic polymer; and 2 wt. % to 15 wt. % of a cationic polymer. A method of making a hair styling composition comprises:... Agent: The Dial Corporation

20150104405 - Aqueous cosmetic preparation: a liquid crystal constituted by the components (A), (B) and (C); obtained by mixing the components (A), (B) and (C); heating the mixture to a temperature equal to or higher than the melting point of the component (A) to homogenize the mixture; and neutralizing the component (B) with the component... Agent: Kao Corporation

20150104408 - Poly(acrylate) polymers for in vivo nucleic acid delivery: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement... Agent: Arrowhead Madison Inc.

20150104406 - Metap-2 inhibitor polymersomes for therapeutic administration: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2... Agent: Children's Medical Center Corporation

20150104407 - Protein-polymer-drug conjugates: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of... Agent:

20150104409 - Human monoclonal antibodies to ctla-4: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within... Agent:

20150104412 - Materials and methods useful for affecting tumor cell growth, migration and invasion: It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance... Agent: The Ohio State University

20150104411 - Novel antitumoral use of cabazitaxel:

20150104410 - Serpin fusion polypeptides and methods of use thereof: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an... Agent:

20150104413 - Immunogenic wt-1 peptides and methods of use thereof: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.... Agent: Memorial Sloan Kettering Cancer Center

20150104414 - Cytokines and neuroantigens for treatment of immune disorders: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.... Agent:

20150104416 - Leukemic stem cell ablation: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.... Agent:

20150104415 - Treatments of hepatitis c virus infection: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.... Agent: Novartis Ag

20150104417 - Compositions comprising a biological control agent and an insecticide: The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.... Agent:

20150104418 - Bacterial composition: A bacterial composition that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11;... Agent: Microbios, Inc.

20150104421 - Calf administered bacterial composition: A feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and pathogen sheading. The additive includes bacteria that inhibits E.... Agent: Microbios, Inc.

20150104420 - Dairy administered bacterial composition: A dairy administered animal feed additive that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits E.... Agent: Microbios, Inc.

20150104419 - Feedlot administered bacterial composition: A feedlot administered animal feed additive that promotes animal health and growth, reduces mortality and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits E. coli O157:H7... Agent: Microbios, Inc.

20150104422 - Fos-based prebiotic and bacterial-based probiotic: A composition including a pathogen inhibiting bacterial probiotic and a fructooligosaccharide (FOS) prebiotic particularly suited as a feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in... Agent: Microbios, Inc.

20150104423 - Use of blood group status iii: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum... Agent: Dupont Nutrition Biosciences Aps

20150104424 - Animal health improvement composition and method: Compositions and methods are provided for improving the health of an animal by reducing certain diseases and by binding certain heavy metals that may be unintentionally introduced into the body of the animal from the environment. Compositions and methods are also provided for improving the feed conversion ratio of an... Agent:

20150104425 - Medical food for high cortisol breast cancer: A method of increasing effectiveness of breast cancer treatment or recovery using a medical food. This breast cancer medical food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The breast cancer medical food, administered correctly, reduces cortisol levels and enhances immune function. This method is... Agent: Cortcontrol, Inc.

20150104426 - Skin-care agent containing pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract: Disclosed is a composition for skin external application containing a Pleurotus ferulae fruiting body extract, a Pleurotus ferulae mycelium extract or a liquid culture obtained by culturing the Pleurotus ferulae mycelium. More specifically, disclosed is a functional composition for skin external application containing 0.001 to 90.0% by weight of a... Agent: Ami Cosmetic Co., Ltd.

20150104434 - Artificial kidney precursor and process for production thereof: The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production... Agent:

20150104431 - Cardiac muscle repair or regeneration using bone marrow-derived stem cells: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be... Agent:

20150104432 - Complete human skin organ generated from culture-expanded cells: Systems and methods can support generation of a full-thickness, human skin organ from tissue culture expanded cells. Human dermal and epidermal progenitor cells can be isolated from human tissues. Isolated cells may be cultured as epidermal cells while other isolated cells may be separately cultured as dermal cells. The cultured... Agent:

20150104428 - Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation: Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering... Agent: University Of Southern California

20150104427 - Enzyme-assisted spatial decoration of biomaterials: A method of producing a hydrogel compromising a spatially-controlled, three-dimensional distribution of one or more bioactive signals is provided. The method compromises illuminating the hydrogel, wherein the hydrogel compromises a polymer bound to a peptide comprising a photolabile protected amino acid, wherein at least one portion of the hydrogel is... Agent: The Regents Of The University Of California

20150104430 - Methods and compositions for generating pancreatic progenitors and functional beta cells from hpscs: Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one... Agent: University Health Network

20150104435 - Methods and compositions for provision of angiogenic factors: Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; for provision of angiogenic factors to cells. In certain embodiments, provision of angiogenic factors to sites of neural degeneration stimulates growth and/or survival of host neurons.... Agent:

20150104429 - Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression: Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with... Agent:

20150104433 - Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains: The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as... Agent:

20150104436 - Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets: Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated... Agent: Chang Gung Medical Foundation, Linkou Branch

20150104437 - Methods for the treatment and diagnosis of bone mineral density related diseases: The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a hone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which... Agent:

20150104438 - Methods of treating cancer using angiogenin or an angiogenin agonist: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing... Agent:

20150104439 - Pharmaceutical removal of neuronal extensions from a degenerating disc: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing... Agent:

20150104441 - Identification of disease-driving antigens: Provided herein is technology relating to treating disease and particularly, but not exclusively, to methods for identifying disease-related antigens by assessing T cell receptor gene frequencies in diseased subjects.... Agent:

20150104440 - Mirna-31 as a diagnostic, prognostic and therapeutic agent in cancer: The current disclosure reveals a complex regulatory pattern between miR-31 and AR, indicating that miR-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that miR-31 directly targets and destabilizes AR mRNA through interaction with the AR mRNA coding sequence showing that... Agent: Cornell University

20150104448 - Anti-complement c1s antibodies and uses thereof: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.... Agent:

20150104443 - Anti-erbb2 antibody variants: The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with... Agent:

20150104446 - Genetic and environmental markers to identify infants at risk for severe lung disease: Provided herein are methods and compositions for determining the susceptibility of infants to severe respiratory syncytial virus (RSV) infections. Also provide are methods of treating said subjects prophylactically to reduce the incidence of such infections.... Agent:

20150104447 - Methods for treating chronic obstructive pulmonary disease using benralizumab: Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.... Agent:

20150104445 - Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein: Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation.... Agent:

20150104444 - Methods related to trastuzumab: The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring... Agent:

20150104442 - Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20150104449 - Variant immunoglobulins with improved manufacturability: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced... Agent:

20150104450 - Ctla-4 variants: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG... Agent:

20150104451 - Ctla4 fusion proteins for the treatment of diabetes: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.... Agent:

20150104452 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent:

20150104453 - Fdf03 antibodies and uses thereof: The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.... Agent: Merck Sharp & Dohme Corp.

20150104456 - Antagonists of il-17 isoforms and their uses: The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.... Agent:

20150104454 - Anti-c.difficile toxin antibodies and associated methods: Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the Clostridium difficile toxin B sequence that comprises an epitope for anti-toxin B antibody. Other embodiments of the invention are directed to the generation of antibodies... Agent: Board Of Regents Of The University Of Oklahoma

20150104459 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.... Agent:

20150104458 - House dust mite allergen: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity... Agent: Biomay Ag

20150104457 - Il-17 antagonist antibodies: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.... Agent:

20150104455 - Methods and compositions for treating and diagnosing acute myocardial infarction: Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or... Agent:

20150104460 - Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration... Agent:

20150104461 - Anti-notch2 nrr antibodies: The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.... Agent:

20150104462 - Use of semaphorin-4d binding molecules for treatment of atherosclerosis: Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to Semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.... Agent:

20150104463 - Methods and kits for predicting the risk of having a cardiovascular event in a subject: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring... Agent: Universite Paris Descartes

20150104464 - Monoclonal antibody therapy for pancreas cancer: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.... Agent:

20150104465 - Il-19 as a biomarker of tslp treatment: The present invention relates to the use of IL-19 as a biomarker of treatment with a TSLP antagonist.... Agent:

20150104466 - Cytomegalovirus disintegrin-like peptides: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents... Agent: Wisconsin Alumni Research Foundation

20150104467 - Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease: Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells... Agent:

20150104468 - Site-specific labeling methods and molecules produced thereby: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue... Agent: Irm LLC

20150104469 - Carriers for improved drug delivery: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.... Agent: Extend Biosciences, Inc.

20150104470 - Immune modulation by peri-lymphatic or intra-lymphatic cell therapy: Disclosed are compositions of matter, methods of treatment, and protocols useful for therapeutic immune modulation using cell therapy administered perilymphatically or intralymphatically. In one particular embodiment, the invention provides means of treating an autoimmune condition by perilymphatic administration of a mesenchymal stem cell population. Said mesenchymal stem cell populations may... Agent:

20150104471 - Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being... Agent: Yeda Research And Development Co. Ltd.

20150104473 - Adjuvant compound: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0... Agent:

20150104472 - C1q peptides and uses thereof: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.... Agent: The Feinstein Institute For Medical Research

20150104474 - Methods of inhibiting gonad maturation: The present invention provides a method of inhibiting maturation of the gonads of a juvenile animal which comprises administering to said juvenile animal an immunologically active molecule (IAM) or a vector comprising nucleic acid encoding an immunologically active molecule, said IAM being specific for a target protein within the gonads... Agent: University Of Nordland

20150104475 - Compositions and methods related to viral vaccines: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.... Agent: The Ohio State University

20150104476 - Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition,... Agent: Curevac Gmbh

20150104478 - Compositions and methods for tissue repair: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and... Agent:

20150104477 - Ubiquitinylated proteins: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and... Agent:

20150104479 - Meningococcus serogroup x conjugate: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a... Agent: Novartis Ag

20150104480 - Increasing virus-like particle yield in plants: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively... Agent:

20150104481 - Water extract of antrodia camphorata for immunostimulatory effect and preparation method thereof: A preparation method for a water extract of the fruiting body of Antrodia camphorata (ACW) is provided. The method includes steps of: (a) providing the fruiting body; and (b) boiling the fruiting body in water to obtain the water extract. This polysaccharide-rich water extract from A. camphorata induces the maturation... Agent: Kaohsiung Medical University

20150104483 - Therapeutic agent for cerebral infarction: The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since... Agent: Mitsubishi Tanabe Pharma Corporation

20150104482 - Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing: Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an... Agent:

20150104484 - Stored strain polyelectrolyte complexes and methods of forming: The present disclosure is directed to articles comprising a polyelectrolyte complex which stores mechanical strain and methods of forming articles comprising a polyelectrolyte complex which stores mechanical strain.... Agent:

20150104485 - Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in... Agent: Lubrizol Advanced Materials, Inc.

20150104487 - Formulation and use thereof: A formulation is claimed, which contains at least one protective substance that is active with respect to cellulose-containing materials, such as wood-containing building materials in the form of solid wood or wood-based materials, and at least one specific compound with dispersing properties. The dispersants are branched comb-shaped polymers with polyether... Agent:

20150104486 - Wound dressing: A wound dressing comprising a mat of gel forming fibres comprising silver, the mat having an open structure reinforced with textile fibres or threads, or fibres or threads of limited absorbency for use in the treatment of wounds.... Agent:

20150104488 - Composite material with a supporting material and an antimicrobial agent: The invention relates to a composite material with at least one supporting material and at least one antimicrobial agent from the group of metals and metal compounds. The composite material comprises at least one hydrophilizing agent which increases the wettability of the surface of the composite material with water in... Agent: Amistec Gmbh & Co. Kg

20150104489 - Therapeutic for treating clostridium difficile infection: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for... Agent: London School Of Hygiene And Tropical Medicine

20150104490 - Growth-inhibited hydroxyapatite, process for its preparation and use: A growth-inhibited hydroxyapatite is contained in agglomerates of prestructured collagen templates, wherein the prestructured collagen templates are denatured or broken up so that fibrillogenesis of the prestructured collagen templates is inhibited. Epitactic hydroxyapatite crystallites with a crystallite size below a critical nucleus radius are formed on the prestructured collagen templates.... Agent:

20150104491 - Sustained-release reservoir implants for intracameral drug delivery: The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the... Agent: Allergan, Inc.

20150104492 - Esculentin 1a derivatives and uses thereof: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced... Agent:

20150104493 - Dissolvable strip for treatment of oral thermal burns: A consumable film adapted to adhere and to dissolve in the oral cavity that provides a local anesthetic and therapeutic agents for the treatment of oral burns or injuries. The film is designed to instantly release benzocaine, or other types of local anesthetic or therapeutic agent, upon adhesion to the... Agent:

20150104495 - Compositions and methods for transdermal delivery of amphetamine: Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system stimulation, such as for the treatment of attention deficit disorder (ADD), attention deficit... Agent: Noven Pharmaceuticals, Inc.

20150104494 - Methods for repair of ear canal tissue defects: Disclosed herein are methods of repairing ear canal tissue defects by administering non-basic fibroblast growth factor (FGF) to the ear canal tissue defect. Also disclosed are delivery devices to administer said non-basic FGF.... Agent:

20150104496 - Composition containing at least one nutrivite, at least one disinfecting or decontaminating, and/or at least one protease-inhibiting active compound and/or active compound complex: The present invention relates to a composition containing at least one nutritive, at least one disinfecting or decontaminating and/or at least one protease-inhibiting active compound and/or active compound complex for the external care and/or treatment of wounds of the human or animal body.... Agent:

20150104498 - Compositions and kits for the removal of irritating compounds from bodily surfaces: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.... Agent:

20150104497 - Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically... Agent:

20150104499 - Transdermal patch and method for delivery of vitamin b12: The present invention is directed to compositions and devices for transdermally administering vitamin B12 to a subject. In one aspect, a vitamin B12 containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B12 combined with selected penetration... Agent: Vita Science LLC

20150104501 - Lipid-supported polymeric functional particles and method of producing the same: The present disclosure relates to functional composite particles produced by filling water-soluble or lipid-soluble polymers into changeable liposomes and a method of producing the same. The present disclosure also relates to an evaluation of specialized biochemical characteristics of composites after the composites are produced using the water-soluble or lipid-soluble polymers... Agent: Research & Business Foundation Sungkyunkwan University

20150104500 - Methods and compositions for preventing a condition: Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from... Agent:

20150104502 - Bolaamphiphilic compounds, compositions and uses thereof: o

20150104503 - Complexes and compositions containing curcumin: A complex is provided, including a phospholipid and curcumin, wherein the phospholipid is sourced from a marine oil.... Agent:

20150104504 - Compositions of statins and omega-3 fatty acids: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood... Agent:

20150104505 - Coated pharmaceutical capsule dosage form: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.... Agent:

20150104506 - Orally available pharmaceutical formulation suitable for improved management of movement disorders: The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent... Agent: Contera Pharma Aps

20150104507 - Formulation of lacosamide: A modified release formulation of lacosamide.... Agent:

20150104508 - Devices, compositions, and methods for fabricating drug delivery systems: Systems, methods, compositions, and devices related to the delivery of one or more biologically active agents to a body include the admixture of one or more biologically active agents with one or more biocompatible polymeric mixtures in a solid-state shear extrusion system. The extrusion systems may include one or more... Agent:

20150104509 - Treating mucosal lesions with hyaluronan delivered from an adhering troche: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying... Agent:

20150104510 - Aliphatic amine polymer salts for tableting: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater... Agent:

20150104512 - Coated tablets and the production thereof: The present invention provides a rapidly disintegrating pharmaceutical formulation in the form of a coated tablet having increased mechanical strength, or hardness. The invention furthermore relates to a process for the production of the coated tablet and to the use of these formulations.... Agent: Merck Patent Gmbh

20150104513 - Coating film, and granules and tablets each utilizing same: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.... Agent: Asahi Kasei Chemicals Corporation

20150104511 - Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine: The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine, festinavir and nevirapine, to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection.... Agent:

20150104514 - Implantable silk-based tissue prostheses: A silk fiber based matrix composition comprising spider silk that can be biodegradable, from the spider species Nephila clavipes (or from genetically engineered bacteria making Nephila clavipes silk), and in the form of a mesh or film.... Agent:

20150104517 - Amino-acid-containing medicinal granular preparation highly easy to take: The present invention aims to provide an amino acid-containing granule preparation improved in the ease of taking medication than conventional products, which disintegrates rapidly. The amino acid-containing granule preparation of the present invention containing granules having a maximum particle size of substantially not more than 1000 μm and a bulk... Agent: Ajinomoto Co., Inc.

20150104518 - Enhanced nitric oxide delivery and uses thereof: Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions.... Agent:

20150104515 - Particles for inhalation having sustained release properties: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of... Agent: Massachusetts Institute Of Technology

20150104519 - Pharmaceutical compositions: Provided herein are formulations and methods for treating pain in human beings. Also provided are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both... Agent:

20150104516 - Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient: Cohesive high-dosage strength micronized active ingredients may be dispersed in dry powder formulations for inhalation comprising carrier particles, by use of the apparatus described herein.... Agent: Chiesi Farmaceutici S.p.a.

20150104520 - Nanoparticle formulations in biomarker detection: The present invention relates to compositions and methods of treatment of cancer patients with cytotoxic drugs in particular the use of cytotoxic drugs encapsulated in a diblock copolymer formulation where the composition is stable in protein free media and less stable in protein containing media such as serum, in particular... Agent:

20150104521 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Abraxis Bioscience, LLC

20150104522 - Use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer: This invention relates to use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil... Agent:

20150104523 - Therapeutic compositions and methods for addressing physiological stresses and aging: Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor... Agent:

20150104524 - Portable oxygen enrichment device and method of use: Lightweight, small, portable devices and methods are disclosed that provide oxygen-enriched air using an ultra rapid adsorption cycle based on advanced molecular sieve materials.... Agent:

20150104525 - Method of decreasing feed conversion ratio in fowl: Methods of decreasing the feed conversion rate for a subject are disclosed.... Agent:

20150104526 - Substituted imidazopyridazines: The present invention relates to substituted imidazopyridazine compounds of general formula I in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition... Agent:

20150104527 - Aqueous ionic solution containing seawater and at least one compound that is originally immiscible with sea water: The invention relates to an aqueous ionic solution, particularly for nasal use, including: at least one seawater solution having an osmolality of between 290 mOsm/kg and 400 mOsm/kg in a weight proportion of between about 30 and 98 wt % relative to the total weight of the composition; at least... Agent: Laboratoire De La Mer

20150104528 - Treatment for depression and other mental conditions with synthetic isotope-modified lithium: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95%... Agent:

20150104529 - Cosmetic composition containing fermented ginseng berry pleurotus ferulae product: Disclosed are a fermented ginseng berry Pleurotus ferulae product and a cosmetic composition containing the same. The fermented ginseng berry Pleurotus ferulae product is useful for anti-oxidation, anti-inflammation, collagen synthesis facilitation, skin wrinkle care, whitening, moisturizing, skin barrier improvement and atopy alleviation.... Agent: Ami Cosmetic Co., Ltd.

20150104530 - Synthetic solid cleanser: The present invention relates to a synthetic solid bar cleanser formulated to clean human skin. More particularly, the present invention relates to synthetic solid cleanser formulations which have pH of about 5.5, the same as human skin, and yet which perform similarly, or superior, to traditional soap.... Agent:

20150104531 - Trans-aconitic acid compounds and uses thereof for inhibiting phosphodiesterase 7: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.... Agent:

20150104532 - Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a method for its preparation: A method of producing a product to correct hypercholesterolemia including pulping fruits of Emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase. The pectinase-treated slurry is filtered to create a solution. The solution is concentrated to create a product. A product having an extract... Agent: Arjuna Natural Extracts, Ltd.

  
04/09/2015 > 129 patent applications in 81 patent subcategories.

20150098894 - Set and method for the production of a radiopharmaceutical: A set for producing a radiopharmaceutical, having a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is... Agent:

20150098895 - Set and method for the production of a radiopharmaceutical: A set for producing a radiopharmaceutical, having a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is... Agent:

20150098896 - Set and method for the production of a radiopharmaceutical: A set for producing a radiopharmaceutical, having: a cation exchange cartridge; a reaction vial containing a precursor marker; a solution vial containing a solvent; an elution vial containing a sterile solution that includes sodium chloride (NaCl) and hydrochloric acid (HCl); a buffer salt. A method for producing a radiopharmaceutical is... Agent:

20150098897 - Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the... Agent: Engenelc Molecular Delivery Pty Ltd

20150098898 - Pharmaceutical composition, method and kit for detecting human melanoma cells: The present disclosure is related to a pharmaceutical composition for detecting human melanoma cells, including: a liposome, a biomolecule having specificity for αvβ3 integrin and a radionuclide. The present disclosure also provides a method using the pharmaceutical composition for detecting human melanoma cells and a kit performing the method. By... Agent:

20150098899 - Particulate materials and compositions for radio therapy: Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of... Agent: Xl Sci-tech, Inc.

20150098901 - Actinium-225 compositions of matter and methods of their use: The present invention is directed to improved methods for generating compositions comprising actinium-225.... Agent:

20150098900 - Anti-fcrh5 antibodies: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.... Agent:

20150098903 - Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits.... Agent:

20150098902 - Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.... Agent:

20150098904 - Eye drop composition: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.... Agent: Aratana Therapeutics Nv

20150098905 - Methods to detect a fungal cell: The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject.... Agent: Rutgers, The State University Of New Jersey

20150098906 - Medicinally marked rolling papers: A method of manufacturing a cigarette and its constituent components including one or more formulations of filler materials and one or more rolling papers each printed with indicia indicative of the respective formulations of filler material. Also the provision of printed material that associates the particular indicia with its associated... Agent:

20150098907 - Foamable composition and uses thereof: The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a... Agent:

20150098910 - Biofilm disruptive compositions: In certain embodiments, the present invention relates to compounds, compositions, and methods for disrupting biofilms. In some embodiments, the compounds and compositions comprise unsaturated long chain alcohols and/or aldehydes, or combinations of such compounds. In further embodiments, the present invention contains therapeutic actives to help reduce and/or eradicate the bacteria... Agent:

20150098908 - Biolubricant polypeptides and therapeutic uses thereof: The invention relates to the field of medicine. In particular, it relates to recombinant cationic polypeptides and their use as biolubricant. Provided is a biolubricant substance comprising the amino acid sequence[(GKGVP)9]n, wherein n is ≧5.... Agent: Rijksuniversiteit Groningen

20150098909 - Soluble fiber lozenge: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent... Agent:

20150098911 - Oral composition: Provided is an oral composition that can sufficiently remove protein staining present on a tooth surface, can effectively prevent adhesion of protein staining on a tooth surface and can provide a good actual feeling of the cleaning effect in the oral cavity. The oral composition comprises the following components (A)... Agent: Kao Corporation

20150098912 - Branched polyether-polyamide block copolymers and methods of making and using the same: Described herein is a polyether polyamide block copolymer as well compositions and products containing the polyether polyamide block copolymer. Methods of making and using the copolymer, the compositions, and products are also described herein.... Agent: Croda International PLC

20150098918 - Cream gels comprising at least one retinoid and benzoyl peroxide: Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent.... Agent:

20150098914 - Glucuronolactone derivatives as self-tanning substances: The invention relates to the use of specific glucuronolactone derivatives as self-tanning substances, as tanning enhancers for dihydroxyacetone or for a mixture of self-tanning substances comprising dihydroxyacetone, for modulation of the colour shade achieved in the case of tanning with dihydroxyacetone or by the mixture or preparation comprising dihydroxyacetone, as... Agent: Merck Patent Gmbh

20150098917 - Method for preventing or treating skin tumor: Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such as brimonidine.... Agent:

20150098915 - Novel surfactant-free self-reversible reverse latex, and use of same as a thickening agent in a cosmetic composition: Disclosed is a self-reversible reverse latex including: a) 25-80% by mass of a cross-linked anionic polyelectrolyte (P), resulting from the polymerisation, for 100 mole percent: i)—of a molar proportion 30% and 95% of monomeric units from at least one monomer including a free, partially- or totally-salified strong acid function; and... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20150098916 - Sunscreen compositions containing an ultraviolet radiation-absorbing polyester: Compositions including an oil phase emulsified in a continuous water phase, the oil phase including a sunscreen agent that includes a UV-absorbing polyester in an amount effective to provide the composition with an SPF of about 10 or greater and which is the polymerization reaction product of monomers including a... Agent:

20150098913 - Sunscreen reapplication reminder device and method: In one general aspect, an apparatus for managing exposure to the sun is disclosed. It includes an aquatic activity control responsive to user interaction and an aquatic activity indicator associated with the aquatic activity control and operative to identify the aquatic activity control. It also includes a terrestrial activity control... Agent:

20150098919 - Skin lightening formulations: A skin care formulation which provides a skin lightening effect virtually immediately upon topical application to the skin and which includes a combination of one or more poly(ethylene) oxides and an acrylic emulsion polymer film former comprising emulsion polymers derived from one or more ethylenically unsaturated monomers.... Agent:

20150098921 - Dihydroxyalkyl substituted polygalactomannan, and methods for producing and using the same: Disclosed are compositions including dihydroxyalkyl substituted polygalactomannan, and the optional further substitution of such with cationic and/or hydrophobic moieties. Method of making such compositions is also disclosed as well as the use of such compositions in industrial applications, fabric laundering, and personal and household care.... Agent:

20150098920 - Personal cleansing compositions and methods: A personal care composition includes a surfactant, a water soluble cationic polymer, a hydrophobic benefit agent, and a hydrophobic cationic polyethylene polymer.... Agent: The Procter & Gamble Company

20150098922 - Compositions comprising polyamine polymer compatible perfume materials: Compositions comprising polyamine polymers and polyamine polymer compatible perfume materials, more specifically, perfume aldehydes that do not react with polyamine polymers are provided.... Agent: The Procter & Gamble Company

20150098923 - Solid form sodium lauryl sulfate (sls) crawling pest elimination composition: A composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in... Agent: Ecolab Usa Inc.

20150098924 - Method for ex-vivo purging in autologous transplantation: The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted.... Agent: Topotarget Switzerland Sa

20150098925 - Compositions and methods for treating cardiovascular diseases using disease-specific promoter: The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention,... Agent:

20150098926 - Methods of treating hepatitis c virus infection: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in... Agent:

20150098927 - Methods for treatment and diagnosis of cancer: The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ)... Agent: Traslational Cancer Drugs Pharma, S.l.

20150098928 - Isoxazoline insecticides: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.... Agent: E.i. Du Pont De Nemours And Company

20150098929 - Probiotic formulation: A probiotic organism which is capable of proliferation in iron-rich media, an environment which is generally unfavourable to probiotic organisms, is described.... Agent: The University Of Bristol

20150098931 - Cooperative medication combination systems: This invention aims to capture and teach the high-level concept of combining doses of medications in unconventionally substandard amounts, for the treatment of medical. pathologies. By combining multiple medications each of which is aimed at treating the same disease process and each in a given substandard dosage, it should allow... Agent:

20150098930 - Diabetic nutritional composition: The present invention provides nutritional compositions as powders, lozenges, tablets or liquids that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic... Agent:

20150098932 - Compositions and methods for treatment of vitiligo: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.... Agent:

20150098933 - Truncated lysosomal acid lipase: Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods... Agent: Synageva Biopharma Corp.

20150098934 - Topical preparations comprising grape seed, folic acid, biotin, bifidobacterium longum and echinacea purpurea: Topical compositions comprising grape seed and at least three of folic acid, biotin, Bifidobacterium longum extract and Echinacea purpurea.... Agent:

20150098935 - Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization: In this application Is described a composition and method for Inducing In a subject anti-hapten antibodies without Inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described. In this application Is disclosed a synthetic liposome composition comprising liposomes (L) containing monophosphoryl lipid... Agent: Walter Reed Army Institute Of Research

20150098936 - Reimmunization and antibody design: The present invention relates to methods for harvesting of antibodies from an antibody library. The antibodies are harvested by utilising a certain epitope that is analogous to the epitope of the antigen used for immunization but that may differ in global physical and biochemical properties allowing the production of antibodies... Agent:

20150098941 - Anti-glypican-3 antibody: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues.... Agent: Xencor, Inc.

20150098940 - Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.... Agent: Oklahoma Medical Research Foundation

20150098937 - Identification of genetic variants: The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or... Agent:

20150098938 - Modulators of acyl-coa lysocardiolipin acyltransferase 1 (alcat1) and uses thereof: Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.... Agent: The Penn State Research Foundation

20150098939 - Novel antagonist antibodies and their fab fragments against gpvi and uses thereof: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab... Agent: Sanofi

20150098942 - Cancer treatment and monitoring methods using ox40 agonists: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.... Agent: Providence Health & Services - Oregon D/b/a Providence Portland Medical Center

20150098944 - Fusion constructs containing active sections of tnf ligands: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular... Agent:

20150098943 - Protein constructs designed for targeting and lysis of cells: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a... Agent:

20150098945 - Anti-robo4 antibody: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the... Agent: Daiichi Sankyo Company, Limited

20150098946 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid... Agent: Genentech, Inc.

20150098947 - Monoclonal olfml-3 antibodies and uses thereof: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.... Agent: Research Development Foundation

20150098948 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.... Agent:

20150098950 - Liquid formulations of tumor necrosis factor-binding proteins: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.... Agent: Ares Trading S.a.

20150098949 - Vegf/dll4 binding agents and uses thereof: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or... Agent: Oncomed Pharmaceuticals, Inc.

20150098951 - Modulators of candida hyphal morphogenesis and uses thereof: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.... Agent: Agency For Science, Technology And Research

20150098952 - Novel therapeutic target and diagnostic marker for asthma and related conditions: CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for... Agent:

20150098953 - Methods of treating a patient having an autoimmune disorder by administering a baff antagonist: Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorder are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round or administration.... Agent:

20150098954 - Compositions and methods related to crispr targeting: Disclosed herein include embodiments related to addition, deletion, or modification of DNA, RNA, or protein in a subject. In an embodiment, the DNA, RNA, or protein is endogenous. In an embodiment, the DNA, RNA, or protein is exogenous. Further embodiments relate to computerized systems for assisting in the disclosed methods.... Agent:

20150098955 - Cd40l-specific tn3-derived scaffolds and methods of use thereof: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune... Agent:

20150098957 - Pcsk9 vaccine: The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in... Agent: Pfizer Vaccines LLC

20150098956 - Recombinant polypeptides comprising mhc class ii a1 domains: Recombinant polypeptides comprising a DRα1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions,... Agent: The United States Government As Represented By The Department Of Veterans Affairs

20150098958 - Influenza nucleoprotein vaccines: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids,... Agent:

20150098959 - Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection: A mucosal immunity-stimulating agent contains a Kampo preparation having a revitalizing activity and a mucosal adjuvant. An oral pharmaceutical composition for treating HPV infection contains at least HPV E7 polypeptide and a Kampo preparation having a revitalizing activity.... Agent:

20150098960 - Treatment of cancers with immunostimulatory hiv tat derivative polypeptides: Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.... Agent:

20150098961 - Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits: The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli. The... Agent:

20150098962 - Modulators of candida hyphal morphogenesis and uses thereof: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.... Agent: Agency For Science, Technology And Research

20150098963 - Methods and compositions for improving the appearance of skin: A method for stimulating collagen synthesis in aging skin cells in need of treatment by topically applying a composition comprising at least one extract from Laminaria genus, at least one extract from the Narcissus genus, and at least one peptide that stimulates SIRT6 activity in the form of a peptide... Agent:

20150098964 - Suppressor cell function inhibition following listeria vaccine treatment: This invention provides methods and compositions for using a live attenuated Listeria for inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.... Agent:

20150098965 - Materials and methods for detecting, preventing, and treating retroviral infection: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that... Agent:

20150098966 - Influenza vaccines: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response... Agent: Kj Biosciences LLC

20150098967 - Rotavirus vaccine compositions and process for preparing the same: Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention... Agent:

20150098968 - Haemophilus parasuis vaccine serovar type four: The present invention is a Haemophilus parasuis vaccine against serovar type 4 capable of triggering a protective immune response when administered to pigs as a killed vaccine. The present invention is also a method for vaccinating swine against Haemophilus parasuis infection, serovar type 4, by a) clonally propagating one or... Agent: Merial Limited

20150098969 - Alternaria peptides: Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of... Agent:

20150098970 - Biomaterial and methods of use thereof for the prevention of post-operative adhesions: Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed.... Agent:

20150098972 - Coated, wet-chemically oxidized aluminum effect pigments, method for the production thereof, coating agent and coated object: A coated wet-chemically oxidized aluminum effect pigment is provided having at least one metal oxide layer having at least one metal oxide which differs from aluminum oxide and an enveloping organic polymer layer, wherein the weight ratio of the metal oxide of the metal oxide layer to aluminum oxide in... Agent:

20150098973 - Composition for application to the skin comprising silsesquioxane resin wax and solid particulate: Provided in various embodiments are compositions for topical application to the skin, comprising a silsesquioxane resin wax, at least one solid particulate with an average particle size greater than 1 micron, and one or more additional waxes.... Agent:

20150098971 - Nail polish compositions: Personal care products for maintaining fingernail and toenail appearance. In particular, nail polish compositions that have a formulation that is both safer and more environmentally-friendly to use. The present nail polish compositions comprise anionic polyester resins such as sodio-sulfonated polyesters and sodio-sulfonated co-polyester-co-polysiloxane copolymers as base resin vehicles.... Agent: Xerox Corporation

20150098974 - Compositions, methods of making a composition, and methods of use: Embodiments of the present disclosure, in one aspect, relate to compositions including a copper/silica nanocomposite and a polymer, methods of making a composition, methods of using a composition, and the like.... Agent: University Of Central Florida Research Foundation, Inc.

20150098975 - Insecticidal water-in-oil (w/o) formulation: The invention relates to an insecticidal water-in-oil (W/O) formulation with at least one insecticidal active substance and at least one burning salt and to the preparation of this formulation. The formulation according to the invention is particularly suitable for the treatment of suitable supports, in particular of paper supports, in... Agent:

20150098976 - Antimicrobial and antifouling catechol-containing polycarbonates for medical applications: Catechol-bearing polycarbonates (catechol polymers) were prepared comprising i) a catechol repeat unit comprising a side chain catechol group, ii) a cationic repeat unit comprising a side chain cationic group selected from the group consisting of quaternary amine groups, quaternary phosphine groups, and combinations thereof, and iii) a PEG repeat unit... Agent: International Business Machines Corporation

20150098977 - Implantable devices formed of non-fouling methacrylate or acrylate polymers: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total... Agent:

20150098978 - Dissolvable-chewable tablet: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet... Agent:

20150098980 - Dexmedetomidine transdermal delivery devices and methods for using the same: Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods... Agent:

20150098979 - Method for imparting enduring beneficial features to flocked surfaces: A method of imparting enduring beneficial features to a hard flocked surface of an article is provided. The method includes encapsulating a desired beneficial agent as a core material in a polymeric microcapsule, and transferring polymeric microcapsule to the surface by a dipping, spraying, or padding application. The beneficial agent,... Agent:

20150098982 - Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions: Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a... Agent:

20150098981 - Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine: Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact... Agent:

20150098983 - Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions: Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagnosed as having withdrawal syndrome. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine... Agent:

20150098984 - Nanolithography using light scattering from particles and its applications in controlled material release: The present disclosure provides hollow nanostructures, methods of forming thereof, and methods of delivery of further nanomaterials utilizing the hollow nanostructures. The hollow nanostructures can be formed by illuminating particles, such as spherical particles, to create a scattering pattern that can be captured on, for example, a photoresist. Thus formed... Agent:

20150098985 - Wound dressings for the controlled release of therapeutic: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by... Agent:

20150098988 - Combination therapy for the treatment of ovarian cancer: This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic.... Agent: Hoffmann-la Roche Inc.

20150098989 - Compounds which inhibit neuronal exocytosis: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in... Agent:

20150098986 - Method for producing elastic vesicles: A method for producing elastic vesicles enveloping active ingredients includes pre-emulsification of a formulation of elastic vesicles and a homogenization step. The pre-emulsification of a formulation of elastic vesicles includes heating and uniformly mixing water of a water phase of the formulation and active ingredients until the active ingredients completely... Agent:

20150098990 - Peptides that target dorsal root ganglion neurons: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular... Agent:

20150098987 - Trans-resveratrol polysaccharide, method of producing thereof, and composition comprising thereof: An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin... Agent:

20150098992 - Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same: Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients... Agent: Hanmi Pharm. Co., Ltd

20150098991 - Oral administration: The present invention is within the field of administration of biopharmaceuticals. More specifically, the invention provides for oral administration of a compound comprising a moiety which confers a desired therapeutic activity; and a polypeptide moiety which binds to albumin.... Agent:

20150098993 - Compositions, process of preparation of said compositions and method of treating inflammatory diseases: The present invention describes a composition and a kit, each having a plurality of compounds, for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA). The invention also relates to a process of obtaining the composition and a method of... Agent:

20150098994 - Pharmaceutical compositions for sleep apnea: Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma... Agent: Collegium Pharmaceutical, Inc.

20150098996 - Nicotine lozenge: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of... Agent:

20150098995 - Tabletting process: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with... Agent:

20150098997 - Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device... Agent:

20150098998 - Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith: The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated... Agent:

20150098999 - Pharmaceutical products and composition comprising specific antiocholinergic agents, beta-2 agonists and corticosteroids: This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, β-2 agonists and corticosteroids.... Agent:

20150099000 - Polyamine derivatives: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.... Agent: Clsn Laboratories, Inc.

20150099001 - Nanocell drug delivery system: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may... Agent:

20150099002 - Means and methods for enhancing weight gain in poultry: The present invention relates to means and methods for enhancing intestinal function in poultry, leading to an increase in food conversion ratio and in total weight gain. Particularly, the present invention relates to insulin-containing feed formulations enhancing intestinal function and weight gain in poultry.... Agent:

20150099003 - Topiramate sustained-release pharmaceutical composition, method for preparing same, and uses thereof: A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China

20150099004 - Aprepitant oral liquid formulations: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.... Agent:

20150099005 - High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy: A high drug loading system is described comprising of at least one anticancer drug; at least one peptide; and at least one nucleic acid.... Agent:

20150099006 - Antibacterial therapy with a whole, leech saliva extract: Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined,... Agent:

20150099007 - Method and system for treatment of biological tissue: A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes mesothelial tissue.... Agent:

20150099008 - Antimicrobial composition: A composition that includes ethylhexyl sulfate or a salt thereof, an alkylbenzenesulfonic acid or a salt thereof, and a carrier. The ethylhexyl sulfate, or salt thereof, and the alkylbenzenesulfonic acid, or salt thereof, are present in a weight ratio of at least about 1:2. The composition can be used for... Agent:

20150099009 - Compositions for treating biofilms and methods for using same: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.... Agent:

20150099010 - Redox signaling gel formulation: Redox signaling gels are disclosed. Such gels include a composition with at least one reactive oxygen species (ROS) and a rheology modifier. Also presented herein is a process for making the gels which includes making the composition by taking the steps of purifying water to produce ultra-pure water, combining a... Agent:

20150099011 - Inactivation of papillomavirus: A method of treating early papillomavirus infection of an orifice of a human or animal body including any canal associated with an orifice, comprising applying a viral inactivation agent to the orifice and/or canal in an amount effective to inactivate a portion of the virus infecting the orifice or canal.... Agent:

20150099012 - Methods for activating retrovirus in latent infected cells, and compounds for use therein: The present invention relates to a method for increasing retrovirus transcription in an infected eukaryotic cell, comprising increasing Wnt pathway signaling in said cell such that transcription of said retrovirus is increased. Also, the present invention relates to a method of treating a subject infected with a retrovirus, said method... Agent:

20150099013 - Sodium thiosulphate for the treatment of ectopic calcifications: The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20150099014 - Method for preparing biocidal and antifouling aqueous compositions comprising hydrobromic acid, urea and sodium hypochlorite: The invention provides a biocidal and antifouling composition comprising hydrobromic acid, urea and sodium hypo-chloride from highly concentrated precursors and a process for manufacturing the composition.... Agent:

20150099015 - Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or... Agent:

20150099016 - Herbal medicinal composition and extract thereof for inducing proliferation of cranial nerve cells and method of manufacturing the same: An herbal medicinal composition and an extract thereof for inducing proliferation of cranial nerve cells and a method of manufacturing the same are disclosed. The herbal medicinal composition includes Ginseng Radix and Aconiti Tuber.... Agent:

20150099017 - Cosmetic formulation: Disclosed are cosmetic toner formulations and methods for their use comprising botanical plant extracts and a cosmetic vehicle.... Agent:

20150099018 - Cosmetic formulation: Disclosed is a topical skin cleanser comprising Silybum marianum fruit extract, Momordica grosvenorii fruit extract, and a cosmetic vehicle comprising at least 50% by weight of the composition of water and disodium EDTA, glycerin, phenoxyethanol, triethanolamine, 3-Iodo-2-propynyl butyl carbamate, and benzyl alcohol.... Agent:

20150099019 - Methods and compositions for treating and preventing signs or symptoms of eye disease: Compositions and methods for the treatment and prevention of at least one of a sign and a symptom associated with an eye disease are disclosed. Preferred compositions could comprise a liquid formulation including Cineraria maritima and at least one of a nonsteroidal anti-inflammatory drug, a carnosine, and a cannabinoid.... Agent:

20150099020 - Aqueous disinfectant composition: A disinfectant composition is provided comprising an extract comprising phenolic compounds obtainable from Rubus species berries, at least one surfactant and water. This aqueous solution can be used for disinfecting solid surfaces, especially those, which do not tolerate solvents such as high concentration ethanol or isopropanol, preferably touch screens or... Agent:

20150099021 - Medicinal composition of extract of seed of emblica officinalis and method of preparing the same: A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing... Agent:

20150099022 - Phytoecdysones for use in improving the muscle quality of obese and/or sarcopenic mammals: Phytoecdysones for use in improving muscle quality in obese and/or sarcopenic mammals, preferably, obese mammals subjected to a low-calorie diet. The phytoecdysones are advantageously incorporated into a food composition. The phytoecdysones can be derived from plants, such as quinoa.... Agent:

  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20150416: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.17753 seconds

PATENT INFO